Wills Eye Hospital is a non-profit eye clinic and hospital in Philadelphia, Pennsylvania. It was established in 1832 and is the oldest continually operating eye-care facility in the United States. It is affiliated with the medical school of Thomas Jefferson University.

During the past decade, Wills Eye Hospital conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 22 clinical trials were completed, i.e. on average, 52.4% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 12 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wills Eye Hospital" #1 sponsor was "Wills Eye" with 28 trials, followed by "Aerie Pharmaceuticals" with 3 trials sponsored, "Aura Biosciences" with 3 trials sponsored, "Mid Atlantic Retina" with 3 trials sponsored and "National Eye Institute (NEI)" with 3 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wills Eye Hospital" #1 collaborator was "Wills Eye" with 4 trials as a collaborator, "National Eye Institute (NEI)" with 3 trials as a collaborator, "Alcon Research" with 2 trials as a collaborator, "Thomas Jefferson University" with 2 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 40 trials.

According to Clinical.Site data, the most researched conditions in "Wills Eye Hospital" are "Glaucoma" (21 trials), "Ocular Hypertension" (7 trials), "Open Angle Glaucoma" (5 trials), "Choroidal Melanoma" (3 trials) and "Diabetic Retinopathy" (3 trials). Many other conditions were trialed in "Wills Eye Hospital" in a lesser frequency.

Most popular intervention types in "Wills Eye Hospital" are "Drug" (27 trials), "Device" (18 trials), "Other" (12 trials), "Procedure" (12 trials) and "Behavioral" (5 trials). Other intervention types were less common.

The name of intervention was led by "AR-13324 Ophthalmic Solution 0.01%" (2 trials), "AR-13324 Ophthalmic Solution 0.02%" (2 trials), "Behavioral Activation" (2 trials), "Latanoprost 0.005%" (2 trials) and "Methylprednisolone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Wills Eye Hospital" are 81 trials for "All" genders.

Currently, there are NaN active trials in "Wills Eye Hospital". undefined are not yet recruiting, 12 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 45 completed trials in Wills Eye Hospital, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Wills Eye Hospital, 3 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 37 trials that are defined as “Not Applicable".

Wills Eye Hospital has several departments that took part in Clinical trials: "Wills Eye Glaucoma Service" - 12 trials, "Ocular Oncology Service, Wills Eye Institute" - 4 trials, "Neuro Ophthalmologic Associates, Wills Eye Hospital, Thomas Jefferson University" - 2 trials